Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 244

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 244
---
,693 18,940 Net cash provided by investing activities115,498 10,555 Cash flows from financing activities:Proceeds from sale of common stock and prefunded warrants in PIPE financing100,002 — Issuance of common stock upon exercise of stock options21 — Payment of PIPE financing related transaction costs(4,822)— Deferred offering costs paid for financing— (10)Net cash provided by (used in) financing activities95,201 (10)Net decrease in cash, cash equivalents and restricted cash198,835 (9,108)Cash, cash equivalents and restricted cash at beginning of period28,734 62,952 Cash, cash equivalents and restricted cash, end of period$227,569 $53,844 Supplemental disclosure of cash flow information:Interest paid during the period$— $58 Supplemental disclosure of non-cash activities:Costs incurred in connection with Private Placement included in accounts payable$632 $— Deferred transaction costs included in accounts payable and accrued liabilities$167 $— Accrued property and equipment$— $540 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

(UNAUDITED)

1. Nature of Organization and Operations

Whitehawk Therapeutics, Inc. (the "Company") is an oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. The Company has a deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, and taking product candidates from the clinic to approval, launch, and commercialization.Current ADC BusinessOn December 19, 2024, the Company entered into an intellectual property license agreement (the “WuXi License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a portfolio of three next generation antibody drug conjugates (“ADCs”) targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need. Refer to Note 12 for further information on the WuXi Biologics License Agreement and its terms.Legacy FYARRO Business.For the periods presented and through the FYARRO Divestiture (as defined below), the Company's lead drug product was FY